Skip to main navigation

Skip to main content

Investor Relations

Home

Press Releases

Investor Relations

Home

Press Releases

Year

April 5, 2021

Passage Bio Receives European Commission Orphan Designation for PBKR03 for Treatment of Krabbe Disease

April 1, 2021

Passage Bio Announces First Patient Dosed in Imagine-1 Study of PBGM01 Gene Therapy for Infantile GM1 Gangliosidosis

March 25, 2021

Passage Bio to Participate in Upcoming April Investor Conferences

March 22, 2021

Passage Bio Appoints Eliseo O. Salinas, M.D., MSc, as Chief Research & Development Officer

March 8, 2021

U.S. Food and Drug Administration Grants Fast Track Designation to Three Passage Bio Gene Therapy Candidates Targeting Rare CNS Disorders

March 3, 2021

Passage Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Highlights

March 2, 2021

Passage Bio to Participate in Upcoming March Investor Conferences

February 24, 2021

Passage Bio to Report Fourth Quarter and Full-Year 2020 Financial Results on March 3, 2021

February 19, 2021

Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors

February 8, 2021

FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying Treatment Options

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 17

Investor Tools

Email Alerts
RSS Feeds
FAQs
Investor Contact

Contact

General inquiries: info@passagebio.com

Investors Contact: passagebio@sternir.com

Two Commerce Square
2001 Market Street, 28th Floor
Philadelphia, PA
19103

Email Alerts

Required fields denoted by an asterisk ().

Alert type
Quote
SEC Filing
End of the Day SEC Filing
Event
News
Weekly Summary

Email

Leave this field blank

© Passage BIO, Inc.. All Rights Reserved

Footer Links - Policy

Privacy Policy